From FPH to RYM, AFT: How are these healthcare stocks faring on NZX?

AFT Pharmaceuticals Limited (NZX:AFT) is expanding its reach abroad with new distribution agreements for its Maxigesic intravenous pain relief and Maxigesic tablets. One of the Company’s flagship products, Maxigesic tablets that combine...

GE Healthcare is the healthcare division of the American multinational conglomerate, General Electric (NYSE: GE). The division alone is valued at US$16.7 billion and provides medical technology and related digital solutions on a global scale. ...

Summary TruScreen Group is in the process to raise NZ$2 million via IPO to raise, plus the dual listing of its shares on ASX. TRU would apply to ASX post the Product Disclosure Statement is lodged on the Offer Register to get admitted on ASX. ...

New Zealand healthcare sector S&P/NZX All Health Care has delivered a decent YTD growth of 28.55% and stood at 3,289.44 on 02 November 2020. The index was up 1.22% at the close on 2 November. The healthcare sector has been one of the top perfor...

  Apart from technology sector, the market players need to look at some stocks from retirement space. It can be said that these stocks have been under the investors’ radar.  This company happens to be a leading retirement village ope...

Summary In December 2019, MET made an announcement about scheme implementation agreement (or SIA) under which EQT, which is a European investment company, would be acquiring all Metlifecare’s shares for the consideration amounting to $7.00...

Summary Fisher & Paykel shares have given a return of 23.4% in 6 months and last traded at $34.90 on 8 October, up by 3.90%. Hospital hardware sales grew by 390%, hospital consumables revenue rose by 48% and overall Hospital product group r...

Summary The healthcare sector, along with the technology sector, has been at the forefront amid the current scenario with several players engaged in developing vaccine/treatment, test kits, and protective equipment against the coronavirus. EBOS...

During these uncertain times, it becomes very important to identify stocks having robust future potential. The past few months have been critical for investors as the outbreak of COVID-19 impacted broader financial markets. However, this stock has ma...

Summary AFT Pharmaceuticals signed an exclusive Maxigesic IV® licensing as well as supply agreement with Medochemie for six European countries. EBOS Group’s revenue rose by 26.5%, and underlying EBITDA increased by 13.4% during FY20. ...